

OMNIPAQUE

Indication	<ul style="list-style-type: none"> • Contrast medium to assess central line tip position^{1,2} 	
INTRAVENOUS	Presentation	<ul style="list-style-type: none"> • Vial: 180 mg/mL
	Dosage	<ul style="list-style-type: none"> • Approximately 0.2–0.3 mL of the 180 mg/mL solution (36–54 mg)¹
	Preparation	<ul style="list-style-type: none"> • Nil required
	Administration	<ul style="list-style-type: none"> • IV injection via central line <ul style="list-style-type: none"> ○ Draw up prescribed dose ○ Administer with x-ray exposure
Special considerations	<ul style="list-style-type: none"> • Contains no preservative². Single use² 	
Monitoring	<ul style="list-style-type: none"> • Nil 	
Compatibility	<ul style="list-style-type: none"> • Do not mix with other drugs² 	
Incompatibility	<ul style="list-style-type: none"> • No incompatibilities found² 	
Interactions	<ul style="list-style-type: none"> • Although no incompatibilities identified, do not mix with other drugs² 	
Stability	<ul style="list-style-type: none"> • Store below 30 °C; do not freeze.² Protect from light² 	
Side effects	<ul style="list-style-type: none"> • Hypersensitivity rare² • Circulatory: peripheral vasodilatation², thrombophlebitis², hypotension², cardiac arrhythmia² • Digestive: vomiting², diarrhoea² • Endocrine: in the recommended dose volumes, does not appear to suppress subsequent thyroid function¹ • Nervous: agitation and seizures² • Urinary: renal impairment² 	
Actions	<ul style="list-style-type: none"> • Can be used as an oral, body cavity and IV contrast medium for radiography² • When given IV, provides opacification of blood vessels and permits radiographic visualisation until sufficient haemodilution occurs or sufficient contrast material has left the site of injection 	
Abbreviations	CVL: central venous line, IV: intravenous,	
Keywords	contrast medium, radio-opaque contrast, radio-opaque dye, peripherally inserted intravenous catheter, PICC line, Iohexol	



The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

References

1. Rath CP, Thomas M, Sullivan D, Kluckow M. Does the use of an iodine-containing contrast agent to visualise the PICC tip in preterm babies cause hypothyroidism? A randomised controlled trial. *Arch Dis Child Fetal Neonatal* Ed 2019;104(2):F212-f4.
2. Therapeutic Goods Administration (TGA). Omnipaque (IOHEXOL) injection for intravascular, oral and body cavities and intrathecal use. [Internet]. Canberra: Australian Government; April 2021 [cited 2021 October 18]. Available from: <https://www.tga.gov.au>.

Document history

ID number	Effective	Review	Summary of updates
NMedQ22.082-V1-R27	01/03/2022	01/03/2027	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)

QR code

